Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong

Medical Principles and Practice

Volumn 14, Issue 5, 2005, Pages 338-341

  Ling, Thomas K W ^a,b   Chun, Mei Ying ^b   Ching, Ching Lee ^a   Zhi, Kai Liu ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acinetobacter baumannii; Antimicrobial resistance; Hong Kong; Shanghai

Indexed keywords

AGAR; AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULPERAZON; SULTAMICILLIN; TIMENTIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; HONG KONG; HUMAN; PATIENT; PRACTICE GUIDELINE;

ACINETOBACTER BAUMANNII; AMIKACIN; AMPICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CHINA; CLAVULANIC ACID; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; FLUOROQUINOLONES; HONG KONG; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; SULBACTAM; THIENAMYCINS; TICARCILLIN;

EID: 23844526812     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086932     Document Type: Article

References (18)

1. Theaker C, Azadian B, Soni N: The impact of Acinetobacter baumannii in the intensive care unit. Anaesthesia 2003;58:271-274.
2. El Shafie SS, Alishaq M, Leni Garcia M : Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in trauma intensive care unit. J Hosp Infect 2004;56:101-105.
3. Herruzo R, de la Cruz J, Fernandez-Acenero MJ, Garcia-Caballero J: Two consecutive outbreaks of Acinetobacter baumannii 1-a in a burn Intensive Care Unit for adults. Burns 2004;30:419-423.
4. Rello J: Acinetobacter baumannii infections in the ICU: customerization is the key. Chest 1999;115:1226-1229.
5. Jones ME, Thornsberry C, Livermore DM, Sahm DF: Prevalence of Acinetobacter spp. isolates with reduced sensitivity to imipenem, as determined by a USA-wide electronic surveillance network. J Antimicrob Chemother 1999;43:429-431.
6. Afzal MS, Livermore DM: Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1998;41:576-577.
7. Ling JM, Ng TK, Cheng AF, Norrby SR: Susceptibilities to 23 antimicrobial agents and beta-lactamase production of blood culture isolates of Acinetobacter sp. in Hong Kong. Scand J Infect Dis 1996;101:21-25.
8. Murray PR, Barron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology, ed 7. Washington, American Society for Microbiology, 1999.
9. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 4. Approved standard M7-A4. Wayne, National Committee for Clinical Laboratory Standards, 1997.
10. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-165.
11. Berlau J, Aucken HM, Malnick H, Pitt TL: Distribution of Acinetobacter spp. on skin of healthy humans. Eur J Clin Microbiol Infect Dis 1999;18:179-183.
12. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, Ortiz C, Cobacho R: Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-1032.
13. Husni RN, Goldstein LS, Arroliga AC, Hall GS, Fatica C, Stoller JKG, Gordon SM: Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999;115:1378-1382.
14. Wisplinghoff H, Perbix W, Seifert H: Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999;28:59-66.
15. Timsit JF, Garrait V, Misset B, Goldstein FW, Renaud B, Carlet J: The digestive tract is a major site for Acinetobacter baumannii colonization in intensive care unit patients. J Infect Dis 1993;168:1336-1337.
16. Dy ME, Nord JA, Labombardi VJ, Kislak JW: The emergence of resistant strains of Acinetobacter baumannii: clinical and infection control implications. Infect Control Hosp Epidemiol 1999;20:565-567.
17. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H: In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multi-drug resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004;48:1586-1592.
18. Wang FD, Lin ML, Lee WS, Liu CY: In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Int J Antimicrob Agents 2004;23:590-595.